Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 4/20 | 0.80 |
| ▸ | MYC | P01106 | 1/20 | 0.68 |
| ▸ | ALPL | P05186 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ACLY | P53396 | 3/20 | 0.56 |
| ▸ | CPT1A | P50416 | 4/20 | 0.56 |
| ▸ | CPT2 | P23786 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750833 | 0.86 | WDR5 (0.65) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL750947 | 0.85 | WDR5 (0.63) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL751570 | 0.84 | WDR5 (0.62) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL750177 | 0.83 | WDR5 (0.61) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL750909 | 0.81 | WDR5 (0.57) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL7578345 | 0.77 | WDR5 (0.73) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL7594909 | 0.77 | NPC1 (0.89) | WDR5MYCALPLNPC1TSHR | |
| SCHEMBL23850850 | 0.77 | ERAP1 (0.75) | WDR5ALPLTSHRCYP2C9LMNA | |
| SCHEMBL23850671 | 0.77 | ERAP1 (0.67) | WDR5ALPLNPC1TSHRACLY | |
| SCHEMBL31587562 | 0.77 | ERAP1 (0.67) | WDR5ALPLNPC1TSHRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | WDR5 2301/4885MYC 4363/4885ALPL 3313/4885 |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | WDR5 2301/4885MYC 4363/4885ALPL 3313/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | WDR5 2301/4885MYC 4363/4885ALPL 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.